6404 Nancy Ridge Drive
About Denovo BiopharmaDenovo Biopharma is a privately-held biotechnology company that provides novel and proprietary biomarker approaches to personalized drug development, including re-evaluating medicines that have failed in general patient populations and studying them in the original indication in biomarker-selected sub-populations. The company offers the first platform and algorithm for de novo genomic biomarker discovery using archived clinical samples. This technology may be especially useful for compounds with suboptimal late-stage trial results. By identifying biomarkers correlated with patients' responses to drug candidates retrospectively, Denovo enables the design and execution of follow-on clinical trials in targeted patient populations with increased likelihood of success.
CEO: Wen Luo
COO: Xiangming Fang
CBO: Robert Little
7 articles with Denovo Biopharma
Denovo Biopharma Acquires Exclusive License of Novel Application of DB102 in the Treatment of Pulmonary Arterial Hypertension
Denovo Biopharma LLC announced it has entered into an exclusive global license agreement with the Stanford University School of Medicine that will enable Denovo to develop and commercialize its lead compound, enzastaurin (DB102).
Denovo Biopharma LLC announced that Wen Luo, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Michael Haller, Ph.D., Chief Financial Officer, will be meeting with investors at the Jefferies 2018 Global Healthcare Conference.
The new 7600 square feet custom-built, state-of-the-art facility hosts Denovo's biomarker discovery platform, US clinical team and serves as Denovo's US headquarters.
Denovo Biopharma Receives FDA's Permission to Proceed a Phase III Clinical Trial with DB102 (Enzastaurin) in the First Line Treatment of High Risk DLBCL
Denovo Biopharma announced today that the FDA has granted DB102 the IND clearance to proceed for a phase III trial to treat Diffuse Large B Cell Lymphoma in the US (ENGINE Study).